ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
W. Roy Smythe
Joseph E. Bavaria
Larry R. Kaiser
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smythe, W. R.
Right arrow Articles by Kaiser, L. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smythe, W. R.
Right arrow Articles by Kaiser, L. R.
Related Collections
Right arrowRelated Article

Ann Thorac Surg 1997;64:949-953
© 1997 The Society of Thoracic Surgeons

Original Article: General Thoracic

Loss of {alpha}v Integrin Expression and Recurrence in Node-Negative Lung Carcinoma

W. Roy Smythe, MD, Dahlia Wasfi, MD, Joseph E. Bavaria, MD, Steven M. Albelda, MD, Larry R. Kaiser, MD

University of Pennsylvania Medical Center Thoracic Oncology Research Laboratory, Division of Cardiothoracic Surgery, Department of Surgery, Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania

Background. Despite "curative" resection, metastases develop in many patients with node-negative (N0) non–small cell lung carcinoma. Alternative biologic markers for this tumor would be useful. Integrins are cell adhesion molecules that are thought to be important in tumor progression, and expression of these molecules previously has been shown to be altered in non–small cell lung carcinoma. We evaluated alterations in integrin expression and clinical outcome.

Methods. Immunohistochemical staining of tumor specimens was performed, and clinical data were reviewed retrospectively.

Results. Data were complete for 42 patients. Half of all patients (21/42) and 9 of 26 patients with negative nodes experienced tumor recurrence during follow-up. Neither histologic type nor tumor differentiation status correlated with recurrence. However, loss of the {alpha}v integrin subunit was associated significantly with recurrence in the N0 group. Seventy-five percent of patients with negative nodes who exhibited recurrence lost {alpha}v expression, compared with only 10% of patients with negative nodes who did not exhibit recurrence (p = 0.012). Alterations of other integrin subunits did not correlate significantly with prognostic follow-up variables.

Conclusions. Loss of {alpha}v expression may serve as a marker for patients with node-negative non–small cell lung carcinoma who are at high risk for recurrence, potentially directing additional therapies.


Related Article

Discussion
Ann. Thorac. Surg. 1997 64: 953. [Extract] [Full Text]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1997 by The Society of Thoracic Surgeons.